NCT06921837View on ClinicalTrials.gov

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2029

Conditions
Gastric Cancer Adenocarcinoma MetastaticGastroesophageal Adenocarcinoma
Interventions
DRUG

BDC-4182

Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist

Trial Locations (3)

Unknown

RECRUITING

AUS Site 2, Darlinghurst

RECRUITING

AUS Site 1, Birtinya

RECRUITING

AUS Site 3, Heidelberg

Sponsors
All Listed Sponsors
lead

Bolt Biotherapeutics, Inc.

INDUSTRY